Daebong LS Strengthens Global Positioning with Six NDAs at Interbiz Bio Forum

Daebong LS, led by CEO Park Jin-oh, announced on the 10th that it has signed six non-disclosure agreements (NDAs) during the 2026 Interbiz Bio Partnering and Investment Forum. This marks a significant step in the company’s strategy to expand its business development network, engaging with over 40 companies and institutions to assess commercialization prospects across improved new drug development, medical devices, and dermocosmetic sectors.

Through the course of the forum and subsequent negotiations, Daebong LS solidified these NDAs with key players, paving the way for in-depth discussions on technology transfer, co-development, and distribution rights. This strategic positioning indicates the firm’s intent to leverage its proprietary technologies and established relationships to facilitate extensive commercial partnerships.

The forum highlighted key innovations from Daebong LS, including L-Erdoesteine, epinaconazole cocrystals, the new crystal form of vonoprazan fumarate, and the innovative azilsartan composition among others. These products represent critical assets in Daebong's pipeline aimed at enhancing treatment protocols in respiratory ailments and fungal infections, indicating a tailored approach to meeting market demands.

Particularly, L-Erdoesteine is being developed to provide a more patient-friendly form of cough suppressant compared to traditional DL-Erdoesteine, enhancing adherence and potentially increasing market penetration. In addition, the epinaconazole cocrystal is suggested to offer a new oral treatment option for onychomycosis, showcasing Daebong’s commitment to addressing gaps in existing therapeutic options.

Building on its non-clinical data and patent portfolio, Daebong LS aims to collaborate with domestic pharmaceutical companies for technology transfer and joint development of their core pipelines, with the target of formal agreements by the end of 2026. This timeline inspires confidence among potential partners and investors regarding the credibility of their developmental strategy.

In the context of medical devices and dermocosmetics, Daebong LS introduced its pharmacy-focused product line, DB JINO, which includes the DB JINO Multi ATO Cream and the DB JINO Algi Bio Cell MD, a class II medical device. The enhancement of pharmacy and clinical distribution networks for these products reflects Daebong’s comprehensive commercialization model, aiming to include exclusive distribution and joint marketing strategies.

A spokesperson from Daebong LS stated, “We continue discussions aimed at technology transfer for L-Erdoesteine and epinaconazole cocrystals by the end of 2026, while propelling the patent-backed commercial strategies for vonoprazan and azilsartan. Furthermore, we are committed to expanding the market reach of the DB JINO line and transforming our R&D achievements into tangible business results.” This statement emphasizes the company's focus on translating research advancements into commercial success, an essential move in a highly competitive landscape.

Ultimately, Daebong’s robust partnerships formed during the Interbiz Bio Forum signal a broader trend towards integrated business models in the beauty and healthcare sectors. Companies investing in collaborative frameworks can enhance brand loyalty and customer trust, setting a precedent for future collaborations in the industry.